Verve Therapeutics is a biotech company pioneering genome editing to permanently reduce the risk of coronary artery disease, with a focus on transforming the approach to heart disease treatment.

Verve Therapeutics, a biotech company, is navigating market volatility while pushing the boundaries of genomic therapies to reduce the risk of coronary artery disease.